Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SonoCloud-9 + Carboplatin in Recurrent Glioblastoma
NCT03744026Phase 2Completed
- Sponsor
- CarThera
- Start
- Feb 2019
- Primary completion
- Jun 2021
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial, sponsored by CarThera. Primary endpoints: Dose Limiting Toxicity at 15 days and Blood-Brain Barrier Opening. Started Feb 2019; status: completed.
Beyond the preview
Go deeper on NCT03744026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03744026.